SCHEMBL157490

SCHEMBL157490

O=c1cc(-c2ccc(O)cc2)oc2cccc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 13/20 1.00
CYP3A4 P08684 6/20 1.00
KMT2A Q03164 6/20 1.00
MAPT P10636 5/20 1.00
MEN1 O00255 5/20 1.00
MAPK1 P28482 3/20 1.00
HPGD P15428 2/20 1.00
RAF1 P04049 1/20 1.00
ALOX15 P16050 3/20 0.79
ALDH1A1 P00352 3/20 0.79
CYP1A1 P04798 3/20 0.79
PKM P14618 3/20 0.79
CYP1B1 Q16678 3/20 0.79
FTO Q9C0B1 3/20 0.79
CYP1A2 P05177 2/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
KDM4E B2RXH2 3/20 0.75
CYP2C9 P11712 3/20 0.75
CYP2C19 P33261 3/20 0.75
HSD17B10 Q99714 3/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethyl Sulfoxide SCHEMBL28821807 0.92 AR (0.84) ARCYP3A4KMT2AMAPTMEN1
Chrysin SCHEMBL5461671 0.89 CYP3A4 (0.82) ARCYP3A4KMT2AMAPTMEN1
5-Hydroxyflavone SCHEMBL158303 0.89 AR (1.00) ARCYP3A4KMT2AMAPTMEN1
5-Hydroxyflavone SCHEMBL30630415 0.89 AR (1.00) ARCYP3A4KMT2AMAPTMEN1
5-Hydroxyflavone SCHEMBL2390993 0.89 AR (1.00) ARCYP3A4KMT2AMAPTMEN1
SCHEMBL6097859 0.88 AR (1.00) ARCYP3A4KMT2AMAPTMEN1
SCHEMBL12636899 0.88 AR (1.00) ARCYP3A4KMT2AMAPTMEN1
5-Hydroxyflavone SCHEMBL28317755 0.87 AR (0.97) ARCYP3A4KMT2AMAPTMEN1
5-Hydroxyflavone SCHEMBL2390943 0.87 AR (0.97) ARCYP3A4KMT2AMAPTMEN1
SCHEMBL6094870 0.87 CYP3A4 (0.85) ARCYP3A4KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195452-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. 2025-06-19 US claimed
EP-4561582-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE Iaterion, Inc. (US) 2025-06-04 EP claimed
CN-119604294-A ERbeta estrogenic compounds and methods of use 益特瑞恩公司 2025-03-11 CN claimed
CN-117562061-A PH value intelligent sensing algae-inhibiting flavone slow-release microsphere and preparation method thereof 浙江大学 2024-02-20 CN claimed
CN-117562060-A Temperature intelligent sensing algae-inhibiting flavone slow-release microsphere and preparation method thereof 浙江大学 2024-02-20 CN claimed
WO-2024026037-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. (US) 2024-02-01 WO claimed
WO-2023150072-A1 COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER SINCLAIR DAVID A (US) 2023-08-10 WO claimed
US-20160367497-A1 METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES WASHINGTON UNIVERSITY 2016-12-22 US claimed
EP-2670404-A1 SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS The Trustees of Princeton University (US) 2013-12-11 EP claimed
CN-103391777-A Sirtuin modulators as virus production modulators UNIV PRINCETON 2013-11-13 CN claimed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO claimed
US-20060002914-A1 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-01-05 US claimed
WO-2006001982-A2 METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES WASHINGTON UNIVERSITY (US) 2006-01-05 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
WO-2003026705-A1 METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS CLEARANT, INC. (US) 2003-04-03 WO claimed
US-20030059338-A1 Methods for sterilizing biological materials using flavonoid/flavonol stabilizers CLEARANT, INC. 2003-03-27 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195452-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE ESR2, ESR1, ESRRB AR 26/4885CYP3A4 210/4885KMT2A 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.